Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis

Autores: Altamirano Barrera Alejandra, Uribe Misael, Lammert Frank, Méndez Sánchez Nahum


Article commented: Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, et al.; Global PBC Study Group. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65: 321-9. Comment: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer death, and accounts for 5.6% of all cancers. Nearly 82% of the approximately 550,000 liver cancer deaths each year occur in Asia. In some regions, cancer-related death from HCC is second only to lung cancer. The most frequent risk factors include chronic viral hepatitis (types B and C), alcohol intake and aflatoxin exposure. However, it has been reported that HCC occurs in 1-6% of patients with primary biliary cholangitis (PBC) per year. In addition HCC surveillance with abdominal imaging and α-fetoprotein is recommended every 6-12 months for patients. Furthermore, some studies suggested that risk factors for the development of HCC in patients with PBC include older age, male sex, presence of portal hypertension, advanced histological stage, and poor response to ursodeoxycholic acid (UDCA).

Palabras clave:

2016-06-24   |   92 visitas   |   1 valoraciones

Vol. 15 Núm.3. Mayo-Junio 2016 Pags. 453-454 Ann Hepatol 2016; 15(3)